

Tanya Gurevich

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8182953/publications.pdf>

Version: 2024-02-01

60
papers

1,432
citations

361045

20
h-index

377514

34
g-index

60
all docs

60
docs citations

60
times ranked

2176
citing authors

#	ARTICLE	IF	CITATIONS
1	Arm swing as a potential new prodromal marker of Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1527-1534.	2.2	136
2	Parkinson's disease phenotype is influenced by the severity of the mutations in the GBA gene. <i>Parkinsonism and Related Disorders</i> , 2018, 55, 45-49.	1.1	90
3	Higher serum cholesterol and decreased Parkinson's disease risk: A statin-free cohort study. <i>Movement Disorders</i> , 2018, 33, 1298-1305.	2.2	89
4	A dose-effect of mutations in the GBA gene on Parkinson's disease phenotype. <i>Parkinsonism and Related Disorders</i> , 2017, 36, 47-51.	1.1	78
5	Reorganization of corticostriatal circuits in healthy G2019S <i>LRRK2</i> carriers. <i>Neurology</i> , 2015, 84, 399-406.	1.5	66
6	Disorders of the Oral Cavity in Parkinson's Disease and Parkinsonian Syndromes. <i>Parkinson's Disease</i> , 2015, 2015, 1-6.	0.6	50
7	Genome-wide mapping of IBD segments in an Ashkenazi PD cohort identifies associated haplotypes. <i>Human Molecular Genetics</i> , 2014, 23, 4693-4702.	1.4	49
8	High Frequency of <i>GBA</i> Gene Mutations in Dementia With Lewy Bodies Among Ashkenazi Jews. <i>JAMA Neurology</i> , 2016, 73, 1448.	4.5	48
9	The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson's disease: A double blind placebo-controlled pilot study. <i>Movement Disorders</i> , 2007, 22, 880-883.	2.2	46
10	Application of the Movement Disorder Society prodromal criteria in healthy G2019S <i>LRRK2</i> carriers. <i>Movement Disorders</i> , 2018, 33, 966-973.	2.2	44
11	Gently does it: Humans outperform a software classifier in recognizing subtle, nonstereotypical facial expressions.. <i>Emotion</i> , 2017, 17, 1187-1198.	1.5	38
12	Quality of life in Parkinson's disease: A gender-specific perspective. <i>Acta Neurologica Scandinavica</i> , 2019, 140, 17-22.	1.0	36
13	Tossing and Turning in Bed: Nocturnal Movements in Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 959-968.	2.2	34
14	Freezing of gait in multiple system atrophy (MSA). <i>Parkinsonism and Related Disorders</i> , 2003, 9, 169-174.	1.1	29
15	A Possible Modifying Effect of the G2019S Mutation in the <i>LRRK2</i> Gene on <i>GBA</i> Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 1249-1253.	2.2	27
16	ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study. <i>Parkinsonism and Related Disorders</i> , 2021, 91, 139-145.	1.1	27
17	Inhaled levodopa in Parkinson's disease patients with OFF periods: A randomized 12-month pulmonary safety study. <i>Parkinsonism and Related Disorders</i> , 2020, 71, 4-10.	1.1	26
18	Revisiting the non-Gaucher- <i>GBA</i> -E326K carrier state: Is it sufficient to increase Parkinson's disease risk?. <i>Molecular Genetics and Metabolism</i> , 2019, 128, 470-475.	0.5	25

#	ARTICLE	IF	CITATIONS
19	Cancer incidence among Parkinson's disease patients in a 10-yr time-window around disease onset: A large-scale cohort study. <i>Parkinsonism and Related Disorders</i> , 2016, 28, 68-72.	1.1	24
20	Concomitant Medication Usage with <sc>Levodopa–Carbidopa</sc> Intestinal Gel: Results from the <sc>COSMOS</sc> Study. <i>Movement Disorders</i> , 2021, 36, 1853-1862.	2.2	24
21	What predicts falls in Parkinson disease?. <i>Neurology: Clinical Practice</i> , 2018, 8, 214-222.	0.8	23
22	Cerebral Imaging Markers of GBA and LRRK2 Related Parkinson–s Disease and Their First-Degree Unaffected Relatives. <i>Brain Topography</i> , 2018, 31, 1029-1036.	0.8	23
23	A cognitive fMRI study in non-manifesting LRRK2 and GBA carriers. <i>Brain Structure and Function</i> , 2017, 222, 1207-1218.	1.2	22
24	Single center experience with medical cannabis in Gilles de la Tourette syndrome. <i>Parkinsonism and Related Disorders</i> , 2019, 61, 211-213.	1.1	22
25	Head-Up Tilt Testing for Detecting Orthostatic Hypotension: How Long Do We Need to Wait?. <i>Neuroepidemiology</i> , 2014, 43, 239-243.	1.1	20
26	Altered reward-related neural responses in non-manifesting carriers of the Parkinson disease related LRRK2 mutation. <i>Brain Imaging and Behavior</i> , 2019, 13, 1009-1020.	1.1	20
27	Cerebral vasomotor reactivity in Parkinson's disease, multiple system atrophy and pure autonomic failure. <i>Journal of the Neurological Sciences</i> , 2006, 243, 57-60.	0.3	19
28	Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or Severity. <i>Movement Disorders</i> , 2022, 37, 190-195.	2.2	19
29	Statin adherence and the risk of Parkinson's disease: A population-based cohort study. <i>PLoS ONE</i> , 2017, 12, e0175054.	1.1	19
30	Levodopa–carbidopa intestinal gel (LCIG) infusion during pregnancy and delivery: First documented case. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1317-1318.	1.1	17
31	Axial motor clues to identify atypical parkinsonism: A multicentre European cohort study. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 33-40.	1.1	17
32	Intact working memory in non–manifesting <i><sc>LRRK</sc>2</i> carriers – an <sc>fMRI</sc> study. <i>European Journal of Neuroscience</i> , 2016, 43, 106-112.	1.2	16
33	Network abnormalities among non–manifesting Parkinson disease related LRRK2 mutation carriers. <i>Human Brain Mapping</i> , 2019, 40, 2546-2555.	1.9	16
34	Mutations in GBA and LRRK2 Are Not Associated with Increased Inflammatory Markers. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1285-1296.	1.5	16
35	Quantification of Daily-Living Gait Quantity and Quality Using a Wrist-Worn Accelerometer in Huntington's Disease. <i>Frontiers in Neurology</i> , 2021, 12, 719442.	1.1	15
36	Survival rates among Parkinson's disease patients who carry mutations in the LRRK2 and GBA genes. <i>Movement Disorders</i> , 2018, 33, 1656-1660.	2.2	14

#	ARTICLE	IF	CITATIONS
37	Dysphagia characteristics in Huntington's disease patients: insights from the Fiberoptic Endoscopic Evaluation of Swallowing and the Swallowing Disturbances Questionnaire. <i>CNS Spectrums</i> , 2019, 24, 413-418.	0.7	14
38	Hierarchical Data-Driven Analysis of Clinical Symptoms Among Patients With Parkinson's Disease. <i>Frontiers in Neurology</i> , 2019, 10, 531.	1.1	13
39	The Effect of GBA Mutations and APOE Polymorphisms on Dementia with Lewy Bodies in Ashkenazi Jews. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 1221-1229.	1.2	12
40	Recognition of emotion from subtle and non-stereotypical dynamic facial expressions in Huntington's disease. <i>Cortex</i> , 2020, 126, 343-354.	1.1	11
41	Subthalamic Neurons Encode Both Single- and Multi-Limb Movements in Parkinson's Disease Patients. <i>Scientific Reports</i> , 2017, 7, 42467.	1.6	10
42	Anemia in men and increased Parkinson's disease risk: A population-based large scale cohort study. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 90-96.	1.1	10
43	Parkinson's disease patients first treated at age 75 years or older: A comparative study. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 69-74.	1.1	9
44	Validation of the Hebrew version of the Movement Disorder Society's Unified Parkinson's Disease Rating Scale. <i>Parkinsonism and Related Disorders</i> , 2017, 45, 7-12.	1.1	9
45	Multidisciplinary intensive outpatient rehabilitation program for patients with moderate-to-advanced Parkinson's disease. <i>NeuroRehabilitation</i> , 2021, 49, 47-55.	0.5	8
46	The Modifying Effect of Age on Survival in Parkinson's Disease: A Population-Based Cohort Study. <i>Neuroepidemiology</i> , 2019, 53, 13-19.	1.1	7
47	Effect of Rivastigmine on Mobility of Patients with Higher-Level Gait Disorder: A Pilot Exploratory Study. <i>Drugs in R and D</i> , 2014, 14, 57-62.	1.1	5
48	Reduced mind wandering in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2017, 44, 38-43.	1.1	5
49	Aberrant dopamine transporter and functional connectivity patterns in LRRK2 and GBA mutation carriers. <i>Npj Parkinson's Disease</i> , 2022, 8, 20.	2.5	5
50	Biochemical markers for severity and risk in GBA and LRRK2 Parkinson's disease. <i>Journal of Neurology</i> , 2021, 268, 1517-1525.	1.8	4
51	Glucocerebrosidase Activity Is Not Associated with Parkinson's Disease Risk or Severity. <i>Movement Disorders</i> , 2022, 37, 651-652.	2.2	4
52	Switching and Combining Device-Aided Therapies in Advanced Parkinson's Disease: A Double Centre Retrospective Study. <i>Brain Sciences</i> , 2022, 12, 343.	1.1	4
53	Medical Cannabis for Gilles de la Tourette Syndrome: An Open-Label Prospective Study. <i>Behavioural Neurology</i> , 2022, 2022, 1-10.	1.1	4
54	Low cerebrospinal fluid volume and the risk for post-lumbar puncture headaches. <i>Journal of the Neurological Sciences</i> , 2020, 417, 117059.	0.3	3

#	ARTICLE	IF	CITATIONS
55	Interrelationships between Survival, Sex, and Blood Pressure in Patients with Multiple System Atrophy. <i>Neuroepidemiology</i> , 2021, 55, 56-61.	1.1	3
56	C9orf72-G4C2 Intermediate Repeats and Parkinson's Disease; A Data-Driven Hypothesis. <i>Genes</i> , 2021, 12, 1210.	1.0	2
57	Rituximab as a Second-Line Treatment for Lymphocytic Vasculitis of the Central Nervous System. <i>Israel Medical Association Journal</i> , 2016, 18, 630-632.	0.1	2
58	Long-Term Persistence and Monotherapy with Device-Aided Therapies: A Retrospective Analysis of an Israeli Cohort of Patients with Advanced Parkinson's Disease. <i>Advances in Therapy</i> , 2022, , 1.	1.3	2
59	Validation of the Hebrew Version of the Unified Dyskinesia Rating Scale. <i>Neuroepidemiology</i> , 2020, 54, 356-362.	1.1	1
60	Repeated Intravenous Amantadine Infusions in Advanced Parkinsonism: Experience of a Large Movement Disorder Center. <i>Israel Medical Association Journal</i> , 2019, 21, 812-816.	0.1	1